Glenmark launches azathioprine in the US
This article was originally published in Scrip
Executive Summary
Glenmark Generics' US subsidiary has launched azathioprine 50mg tablets, a generic version of GlaxoSmithKline's Imuran tablets. Glenmark has received marketing rights for the product through an exclusive partnership. Azathioprine is indicated as an adjunct for the prevention of rejection in renal homotransplantations and is also used for the management of active rheumatoid arthritis. Sales of the product for the 12 months ended June 2008 were about $36 million. Glenmark expects to augment its portfolio of products based on its own filings with external partnerships. The company is authorised to distribute 130 stock keeping units (SKUs) in the US and has 40 ANDAs in various stages of the approval process with the US FDA.